MYCN and neuroblastoma: To investigate this insight in a more clinically relevant in vivo setting, we used the extensively characterized Th-MYCN genetically engineered mouse (GEM), known to mirror many clinical features of high-risk MYCN-driven neuroblastoma,51,52 in which MYCN is expressed under the control of the tyrosine hydroxylase (Th) promoter.